Loading...
XNAS
SLN
Market cap465mUSD
Jul 09, Last price  
9.86USD
1D
-0.90%
1Q
72.08%
IPO
-48.11%
Name

Silence Therapeutics PLC

Chart & Performance

D1W1MN
XNAS:SLN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.62%
Rev. gr., 5y
-36.65%
Revenues
559k
-98.71%
1,947,0004,047,0002,209,0001,723,0002,366,000720,131163,000117,00015,0000770,00016,0000244,0005,479,00012,415,00017,653,04725,375,00043,258,000559,000
Net income
-89m
L+95.57%
-3,826,000-5,108,000-7,435,000-7,471,000-8,795,000-5,737,000-26,284,000-9,002,000-11,088,000-6,645,000-8,440,000-1,618,000-18,411,000-19,582,000-32,547,000-39,410,000-41,032,025-43,267,000-45,309,000-88,612,000
CFO
-62m
L+15.21%
-4,030,000-3,833,000-6,981,700-4,648,000-10,552,000-5,110,000-4,876,000-6,756,000-9,458,000-8,255,000-10,066,000-9,599,000-16,760,0001,727,000-10,776,0009,185,629-57,044,000-39,350,000-54,050,447-62,271,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the company's approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, meticulously crafted to precisely target specific disease-causing genes, predominantly within the liver. This mechanism involves creating short interfering RNA (siRNA) molecules that activate the body's intrinsic RNA interference pathway, effectively breaking down messenger RNA (mRNA) sequences responsible for producing particular disease-associated proteins inside cells. Silence Therapeutics is actively developing a pipeline of therapeutic candidates. This includes SLN360, currently in Phase I clinical trials for the treatment of cardiovascular disease characterized by elevated lipoprotein levels. Furthermore, SLN124 is progressing through Phase I clinical trials for both non-transfusion dependent thalassemia and myelodysplastic syndrome, with ongoing development also focused on polycythemia vera. The company has forged strategic partnerships to broaden its reach and capabilities. It collaborates with AstraZeneca PLC to identify, develop, and commercialize small interfering RNA therapeutics addressing cardiovascular, renal, metabolic, and respiratory conditions. Another alliance is with Mallinckrodt Pharma IP Trading DAC, centered on developing and marketing RNAi drug targets designed to inhibit the complement cascade in various complement-mediated disorders. Additionally, Silence Therapeutics is working with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three confidential targets, utilizing its mRNAi GOLD platform. The organization, which operated as SR Pharma plc until its rebranding in May 2007, continues its mission under the name Silence Therapeutics plc.
URL
https://www.silence-therapeutics.com/
IPO date
Jan 05, 2010
Employees
122
Domiciled in
GB
Incorporated in
GB

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT